Translation of Neurological Biomarkers to Clinically Relevant Platforms
- 8 June 2009
- book chapter
- Published by Springer Science and Business Media LLC
- Vol. 566, 303-313
- https://doi.org/10.1007/978-1-59745-562-6_20
Abstract
Like proteomics more generally, neuroproteomics has recently been linked to the discovery of biochemical markers of central nervous system (CNS) injury and disease. Although neuroproteomics has enjoyed considerable success in discovery of candidate biomarkers, there are a number of challenges facing investigators interested in developing clinically useful platforms to assess biomarkers for damage to the CNS. These challenges include intrinsic physiological complications such as the blood–brain barrier. Effective translation of biomarkers to clinical practice also requires development of entirely novel pathways and product development strategies. Drawing from lessons learned from applications of biomarkers to traumatic brain injury, this study outlines major elements of such a pathway. As with other indications, biomarkers can have three major areas of application: (1) drug development; (2) diagnosis and prognosis; (3) patient management. Translation of CNS biomarkers to practical clinical platforms raises a number of integrated elements. Biomarker discovery and initial selection needs to be integrated at the earliest stages with components that will allow systematic prioritization and triage of biomarker candidates. A number of important criteria need to be considered in selecting clinical biomarker candidates. Development of proof of concept assays and their optimization and validation represent an often overlooked feature of biomarker translational research. Initial assay optimization should confirm that assays can detect biomarkers in relevant clinical samples. Since access to human clinical samples is critical to identification of biomarkers relevant to injury and disease as well as for assay development, design of human clinical validation studies is an important component of translational biomarker research platforms. Although these clinical studies share much in common with clinical trials for assessment of drug therapeutic efficacy, there are a number of considerations unique to these efforts. Finally, platform selection and potential assay commercialization need to be considered. Decisions regarding whether or not to seek FDA approval also significantly influence translational research structures.Keywords
This publication has 22 references indexed in Scilit:
- Neuroproteomics and systems biology‐based discovery of protein biomarkers for traumatic brain injury and clinical validationProteomics – Clinical Applications, 2008
- Use of biomarkers for diagnosis and management of traumatic brain injury patientsExpert Opinion on Medical Diagnostics, 2008
- Classification of Traumatic Brain Injury for Targeted TherapiesJournal of Neurotrauma, 2008
- Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometryJournal of Neurochemistry, 2007
- Clinical Significance ofαII-Spectrin Breakdown Products in Cerebrospinal Fluid after Severe Traumatic Brain InjuryJournal of Neurotrauma, 2007
- Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injuryJournal of Neurochemistry, 2006
- Concurrent calpain and caspase-3 mediated proteolysis of αII-spectrin and tau in rat brain after methamphetamine exposure: A similar profile to traumatic brain injuryLife Sciences, 2005
- Rapid Discovery of Putative Protein Biomarkers of Traumatic Brain Injury by SDS–PAGE–Capillary Liquid Chromatography–Tandem Mass SpectrometryJournal of Neurotrauma, 2005
- Design and Analysis of Phase III Trials with Ordered Outcome Scales: The Concept of the Sliding DichotomyJournal of Neurotrauma, 2005
- Accumulation of non‐erythroid αII‐spectrin and calpain‐cleaved αII‐spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in ratsJournal of Neurochemistry, 2001